Back to products

Sold out

Zelboraf 240 mg Tablet

Brand Name: Zelboraf

Molecule: Vemurafenib

Strength: 240 mg

Quantity: 56 Tablets

Form: Tablet

Packaging Type: Bottle

Manufacturer/Marketed By: Roche

Country of Origin: USA

Image	Product	Manufacturer / Marketed By	Price
	LuciVemu 240 mg Tablet	Lucius Pharma	Ask for Price

Description

Zelboraf 240 mg Tablet contains vemurafenib, a targeted anticancer medicine classified as a BRAF kinase inhibitor. It is used in the treatment of certain cancers that carry a specific mutation in the BRAF gene, most commonly BRAF V600 mutation–positive melanoma. This mutation causes abnormal signaling that promotes uncontrolled growth of cancer cells. By targeting this pathway, vemurafenib may help slow tumor growth when used as prescribed by a qualified healthcare professional. Zelboraf is typically prescribed for patients whose tumors have been confirmed to carry the BRAF V600 mutation through appropriate diagnostic testing. The medicine is taken orally and is usually part of a treatment plan managed by an oncologist. In some cases, it may be used in combination with other cancer therapies depending on clinical guidelines and patient-specific factors. Patients receiving treatment with

Benefits

Targets the BRAF V600 mutation, a driver of tumor growth in some cancers
Precision oncology therapy based on tumor genetic profiling
Oral tablet formulation for convenient administration
May help slow cancer progression in patients with confirmed BRAF mutation
Used in modern targeted therapy regimens

Indications and Usage

Zelboraf (vemurafenib) may be prescribed for:

Unresectable or metastatic melanoma with BRAF V600 mutation
Certain patients with Erdheim-Chester disease (ECD) with BRAF mutation
Treatment based on confirmed genetic testing for BRAF mutation

Use is determined by an oncologist following molecular diagnostic testing.

How it Works

Vemurafenib works by inhibiting the BRAF protein kinase, specifically the mutated BRAF V600 variant found in certain cancers. The BRAF protein is part of the MAPK signaling pathway, which regulates cell growth and survival. When mutated, this pathway becomes overactive, causing uncontrolled cell division.

By blocking the activity of mutated BRAF proteins, vemurafenib disrupts abnormal signaling that promotes cancer cell proliferation. This targeted mechanism can help slow tumor growth in patients whose cancers carry the BRAF V600 mutation when the medicine is used as prescribed and monitored by an oncology specialist.

Dosage & Administration

Zelboraf tablets are taken orally, typically twice daily, unless directed otherwise by a healthcare professional.
Tablets should be swallowed whole with water.
The medicine may be taken with or without food.
Dose adjustments may be required depending on tolerance and side effects.
Treatment continues until disease progression or unacceptable toxicity, as determined by the oncologist.

Side Effects

Common side effects

Joint pain (arthralgia)
Rash
Fatigue
Hair thinning or hair loss
Photosensitivity (increased sensitivity to sunlight)
Nausea

Serious side effects

Severe skin reactions
Secondary skin cancers such as cutaneous squamous cell carcinoma
Heart rhythm abnormalities (QT prolongation)
Liver function abnormalities
Eye problems such as uveitis

Patients should seek medical attention if serious symptoms occur.

Warning and Precaution

Risk of secondary skin cancers, requiring regular dermatologic monitoring
Increased photosensitivity, requiring sun protection
Possible heart rhythm abnormalities (QT prolongation)
Liver function abnormalities may occur
Eye disorders such as uveitis or retinal issues
Inform healthcare providers about all medications and supplements being used
Pregnancy should be avoided during treatment

Patient Guidance

Take the medicine exactly as prescribed by your oncologist
Attend scheduled monitoring appointments and laboratory tests
Protect skin from sun exposure using sunscreen and protective clothing
Report symptoms such as new skin lesions, vision changes, or severe rash
Inform your doctor about all medications and supplements you take
Do not stop treatment without consulting your healthcare provider

Clinical Trial & Approvals

Vemurafenib has been evaluated in several clinical trials for patients with BRAF V600 mutation–positive melanoma. The BRIM-3 clinical trial demonstrated improved survival outcomes compared with certain traditional chemotherapy treatments. Based on these results, vemurafenib received regulatory approvals from agencies including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for specific oncology indications.

References

U.S. Food and Drug Administration (FDA) – Zelboraf Prescribing Information
https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202429s025lbl.pdf
European Medicines Agency (EMA) – Zelboraf (vemurafenib) Product Information
https://www.ema.europa.eu/en/medicines/human/EPAR/zelboraf
National Cancer Institute – Vemurafenib Drug Information
https://www.cancer.gov
Drugs.com – Vemurafenib Drug Information
https://www.drugs.com
ClinicalTrials.gov – Vemurafenib Clinical Studies
https://clinicaltrials.gov

Prescription & documentation note

Zelboraf 240 mg Tablet is typically supplied against a valid prescription. For international orders, patients may be required to provide documentation such as a licensed physician’s prescription, identification, and country-specific import documentation, depending on destination regulations. MedsMonk may assist with documentation guidance where applicable.

FAQ

What is Zelboraf 240 mg Tablet used for?+

It is used to treat melanoma with BRAF V600 mutation and certain other BRAF mutation–positive conditions as prescribed by a doctor.

What is the active ingredient in Zelboraf?+

The active ingredient is vemurafenib, a BRAF kinase inhibitor.

Is genetic testing required before using Zelboraf?+

Yes. Treatment usually requires confirmation of a BRAF V600 mutation in the tumor.

How is Zelboraf taken?+

It is typically taken twice daily by mouth, unless your doctor advises otherwise.

Can Zelboraf cause sun sensitivity?+

Yes. Patients may experience increased sensitivity to sunlight and should use sun protection.

Can Zelboraf interact with other medicines?+

Yes. Certain medicines may affect heart rhythm or liver enzymes, so all medications should be disclosed to a healthcare provider.

Is Zelboraf chemotherapy?+

No. Zelboraf is a targeted cancer therapy, not traditional chemotherapy.

Is a prescription required for Zelboraf?+

Yes. Zelboraf is a prescription-only oncology medicine.

Ruxolitinib Tablets Receive FDA Approval for Hematologic Malignancies

The U.S. Food and Drug Administration (FDA) has approved Ruxolitinib tablets for the treatment of certain hematologic malignancies, marking another

May 18, 2026

Tovorafenib Approved in Europe for Children with BRAF-Altered Low-Grade Glioma

n Medical Review: This article was reviewed by Dr. Sophie Reynolds on May 14, 2026.n n This marks an important

May 14, 2026

FDA Fast-Tracks Plixorafenib for BRAF V600E–Mutated Brain Tumors

n Medical Review: This article was reviewed by Dr. Sophie Reynolds on April 14, 2026.n n Brain tumors, especially high-grade

April 14, 2026

Rated 0 out of 5

0 reviews

Rated 5 out of 5

Rated 4 out of 5

Rated 3 out of 5

Rated 2 out of 5

Rated 1 out of 5

Reviews

Clear filters

There are no reviews yet.

Only logged in customers who have purchased this product may leave a review.